Industries > Pharma > Global Anti-Obesity Drugs Market Forecast 2017-2027

Global Anti-Obesity Drugs Market Forecast 2017-2027

Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others

PUBLISHED: 12 January 2017
PAGES: 205
PRODUCT CODE: PHA0161
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0161 Categories: ,

The global anti-obesity drugs market is expected to grow at a CAGR of 27.1% in the first half of the forecast period and CAGR of 38.7% in the second half of the forecast period. The market is expected to grow at a CAGR of 32.8% from 2016 to 2027. The market is estimated at $1,058 million in 2016, $3,513 million in 2021, and $24,063 million in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 205-page report you will receive 78 tables and 140 figures – all unavailable elsewhere.

The 205-page report provides clear detailed insight into the global anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Anti-Obesity Drugs Market Forecast 2017-2027

Report Scope
Global Anti-Obesity Drugs market forecasts from 2017-2027

• Anti-Obesity Drugs National market forecasts from 2017-2027, covering:
– United States
– Germany
– France
– United Kingdom
– Italy
– Spain
– Japan
– China
– India
– Brazil
– Russia
– RoW

• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Mechanisms of Action:
– Incretin mimetics/GLP-1 agonists
– SNDRIs
– Lipase inhibitors
– Serotonin receptor agonists
– Sympathomimetic-GABA receptor agonists
– Sympathomimetics
– Others

• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Duration of Therapy:
– Short-term Drugs
– Long-term Drugs

• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Innovator vs Generic Drugs

• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Prescription vs OTC Drugs

• Analysis of the key factors driving and restraining the growth of the anti-obesity drugs market from 2017-2027

Pricing and Reimbursement overview of the anti-obesity drugs market

• Assessment of selected leading companies that hold major market shares in the anti-obesity drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Anti-Obesity Drugs Market and leading companies. You find data, trends and predictions.

Buy our report today Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

READ

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Categories